Roche Launches Hostile Bid for Illumina to Reclaim Next-Gen Sequencing Mantle

Jan 25, 2012, 09:00 AM by Michael Croft

New York Times | Roche, the Swiss drug maker, has launched a $5.7 billion hostile bid for Illumina, going directly to the company’s shareholders. In early trading, Illumina shares soared some 40%, trading above the $44.50 Roche was willing to offer.

January 25, 2012 | Roche, the Swiss drug maker, has launched a $5.7 billion hostile bid for Illumina, going directly to the company’s shareholders. In early trading, Illumina shares soared some 40%, trading above the $44.50 Roche was willing to offer. New York Times